16 results about "Cannabidiolic acid" patented technology

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

The present application relates to cannabidiol esters, compositions comprising them and their use in the treatment of a variety of different diseases, disorders and symptoms.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed herein are methods for converting cannabidiol, cannabidiolic acid and analogs thereof into Δ8-tetrahydrocannabinol, Δ8-tetrahydrocannabinolic acid and analogs thereof. In particular, there is provided a method for converting a compound of Formula (I) as defined herein into a compound of Formula (II) as defined herein, the method comprising heating the compound of Formula (I) and a Lewis acidic heterogeneous reagent in an aprotic-solvent system to provide a compound of Formula (II), wherein the Lewis-acidic heterogeneous reagent is acidic alumina.

The invention discloses a method for rapidly detecting ten cannabinoids in industrial hemp fresh floral leaves based on an HPLC (High Performance Liquid Chromatography) method. The method comprises the following steps: S1, preparing a mixed standard solution; s2, pretreatment of a fresh industrial cannabis sativa floral leaf sample: liquid nitrogen grinding wall breaking, solvent ultrasonic extraction and low-temperature centrifugation are carried out, and a supernatant is taken for sample preparation; and S3, high performance liquid chromatography determination. The ten cannabinoids disclosed by the invention comprise cannabidiol (CBD), cannabidiol acid (CBDA), hypocannabidiol (CBDV), tetrahydrocannabinol acid (THCA), delta 9-tetrahydrocannabinol (delta 9-THC), delta 8-tetrahydrocannabinol (delta 8-THC), hypocannabinol (THCV), cannabinoid phenol (CBG), cannabinol (CBN) and cannabinocene (CBC). According to the method, the situation that carboxylic acid cannabinoid in fresh floral leaves is prone to decarboxylation conversion in the pretreatment process is fully considered, low-temperature extraction is conducted through liquid nitrogen grinding wall breaking, and it is ensured that carboxylic acid cannabinoid is stable. The detection method disclosed by the invention realizes high-throughput detection of 10 cannabinoids, can rapidly, objectively, accurately and synchronously detect various cannabinoids including carboxylic acid cannabinoids in fresh industrial hemp floral leaves, and has the advantages of short detection time (not exceeding 15 minutes), accurate quantification, reliable result, high efficiency and the like; and a reliable basis can be provided for industrial hemp characteristic variety breeding and scientific harvesting.

The present application relates to cannabidiol esters, compositions comprising them and their use in the treatment of a variety of different diseases, disorders and symptoms.

The present disclosure provides engineered variants of a cannabidiolic acid synthase (CBDAS) polypeptide comprising an amino acid sequence of SEQ ID NO:3 with one or more amino acid substitutions, nucleic acids comprising nucleotide sequences encoding said engineered variants, methods of making modified host cells comprising said nucleic acids, modified host cells expressing said engineered variants, methods of producing cannabinoids or cannabinoid derivatives, and methods of screening engineered variants of the cannabidiolic acid synthase (CBDAS) polypeptide.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

Provided are pharmaceutical compositions comprising cannabis such that when combusted produces cannabidiolic acid (CBDA) for inhalation. Also provided are pharmaceutical composition for inhalation by a subject comprising tetrahy drocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabigerol (CBG). Also provided are methods of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation. Methods of use of embodiments of the pharmaceutical composition and kits comprising embodiments of the pharmaceutical composition are provided herein. Unit dosage form medicaments and compositions for vaporization by a subject comprising cannabinoids are also disclosed herein.

The present invention relates to the field of biotechnology, and in particular to a method for extracting cannabidiol acid. The present invention provides a method for extracting cannabidiol acid, comprising: sterilizing industrial hemp, mixing it with a strain with a deposit number of CGMCC: 1.3604, fermenting it, adjusting the pH value to be alkaline, ultrasonically extracting it, filtering it, collecting the extract, extracting it with an organic solvent, and purifying it to obtain the cannabidiol acid. The present invention provides a method for extracting cannabidiol acid, which fills the gaps in the prior art, and most of the current extraction methods for industrial hemp are based on chemical extraction methods. The present invention uses microorganisms to increase the selection of methods for extracting related components. By the method provided by the present invention, the cannabidiol acid extracted has a high purity.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

The present disclosure provides methods and kits for characterizing Cannabis plants. Methods and kits of the present disclosure include detection / amplification of one or more enzymes involved in the production of cannabinoids, such as, for example, tetrahydrocannabinolic acid (THCA) synthase and / or cannabidiolic acid (CBDA) synthase.

A fixed dose combination formulation drug comprised of up to five cannabinoids, namely cannabidiol, cannabichromene, cannabidiolic acid, cannbidovorin, and cannabigerol, one or more mushroom biomasses of Coroilus versicolor or Trametes versicolor or their respective active peptides, polysaccharides, or polysaccharidopeptides, and optionally of up to three terpenes, namely alpha-terpinene, bisabolol, and camphene, in an orally available pharmaceutical carrier, for the alleviation of the adverse effects of cancer chemotherapy agents, including adverse effects on the gastrointestinal tract, the chemoreceptor trigger zone, and the peripheral nervous system, and that shows activity adjunctively against ovarian cancer, particularly ovarian cancer that is therapeutically platinum-resistant or platinum-sensitive, as well as method of their manufacture, and methods of their therapeutic administration to a patient.

The present invention generally pertains to methods of characterizing crosslinking sites of a protein of interest. In particular, the present invention pertains to the use of size exclusion chromatography, peptide mapping and subunit analysis to identify and quantify crosslinking sites of a protein of interest and determine a contribution of crosslinking to the formation of high molecular weight species.